Clonazepam Impurities in Aurobindo's Quality Control
Aurobindo Pharma's clonazepam tablets (e.g., ANDA 077032 for 0.5 mg strength) follow USP monograph standards for quality control, which specify testing for process-related and degradation impurities.[1] Key impurities include:
- 2-Amino-2'-chlorobenzophenone: A primary synthetic intermediate impurity, limited to NMT 0.5% in USP.[2]
- 2'-Chlorobenzophenone: Another process impurity from synthesis, controlled at NMT 0.2%.[2]
- Nitroso-clonazepam: A potential nitrosamine impurity flagged in recent FDA inspections of Aurobindo facilities; levels tested to below 96 ng/day acceptable intake.[3][4]
- Clonazepam open ring epoxide: Degradation product from epoxide ring opening, limited to NMT 0.1%.[2]
These are monitored via HPLC in Aurobindo's stability and release testing, as detailed in their FDA-approved ANDA filings.[1]
Why Nitrosamine Impurities Matter for Aurobindo Clonazepam
FDA's 2023 warning letter to Aurobindo cited inadequate nitrosamine control in clonazepam API from their India site, prompting enhanced testing for N-nitroso-clonazepam and analogs. Aurobindo responded by validating methods detecting down to 0.03 ppm and confirming levels below limits.[3][5] No recalls issued specifically for clonazepam impurities as of 2024.
How Aurobindo Tests These Impurities
Testing uses USP <621> chromatography:
- HPLC with UV detection at 254 nm for benzophenone-related impurities.
- LC-MS/MS for nitrosamines per FDA guidance.
Batch release requires all impurities < specified limits; stability data shows no significant increase over 24-36 months.[1][6]
Recalls or Issues Linked to Impurities
Aurobindo faced a 2022 recall (D-0327-2022) for clonazepam 2 mg tablets due to "CGMP deviations," not impurity-specific, but FDA notes ongoing impurity monitoring post-inspection.[7] No OOS results publicly tied to clonazepam impurities.
Comparison to Other Generic Makers' Clonazepam QC
| Maker | Key Impurities Tested | Nitrosamine Focus |
|-------|-----------------------|-------------------|
| Aurobindo | 2-Amino-2'-chlorobenzophenone, nitroso-clonazepam | Yes, post-2023[3] |
| Accord | Similar USP set + epoxide | Limited nitrosamine data |
| Mylan | Benzophenones primary | Yes[8] |
| Teva | Adds process unknowns | Yes[8] |
All adhere to USP, but Aurobindo's recent scrutiny drives stricter nitrosamine limits.[1][2]
[1]: FDA ANDA 077032 Label
[2]: USP Monograph: Clonazepam Tablets
[3]: FDA Warning Letter to Aurobindo (2023)
[4]: FDA Nitrosamine Guidance
[5]: Aurobindo FDA Response (2023)
[6]: Aurobindo Stability Data via FDA
[7]: FDA Recall Database
[8]: DrugPatentWatch.com - Clonazepam Patents/Impurities